Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

Bentz, J and O'Connor, MP and Bednarczyk, D and Coleman, J and Lee, C and Palm, J and Pak, YA and Perloff, ES and Reyner, E and Balimane, P and Brannstrom, M and Chu, X and Funk, C and Guo, A and Hanna, I and Heredi-Szabo, K and Hillgren, K and Li, L and Hollnack-Pusch, E and Jamei, M and Lin, X and Mason, AK and Neuhoff, S and Patel, A and Podila, L and Plise, E and Rajaraman, G and Salphati, L and Sands, E and Taub, ME and Taur, JS and Weitz, D and Wortelboer, HM and Xia, CQ and Xiao, G and Yabut, J and Yamagata, T and Zhang, L and Ellens, H (2013) Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria. DRUG METABOLISM AND DISPOSITION. pp. 1347-1366.

Item Type: Article
Additional Information: pubid: 245 nvp_institute: NIBR contributor_address: Drexel Univ, Dept Biol, Philadelphia, PA 19104 USA ; Optivia, Biotechnol, Menlo Pk, CA USA ; Pfizer Inc, Dept Pharmacokinet Dynam & Metab, San Diego, CA USA ; CVGI iMed DMPK, AstraZeneca R&D Molndal, Innovat Med, Molndal, Sweden ; Eli Lilly & Co, Lilly Res Labs, Investigat Drug Disposit, Indianapolis, IN 46285 USA ; BD GentestSM Contract Res Serv, BD Biosci Discovery Labware, Woburn, MA USA ; Bristol Myers Squibb, Pharmaceut Candidate Optimizat, Bristol Myers Squibb, Princeton, NJ USA ; Merck & Co Inc, Dept Pharmacokinet Pharmacodynam & Drug Metab, Rahway, NJ USA ; F Hoffmann La Roche, Nonclin Drug Safety, Basel, Switzerland ; Hoffmann La Roche, Nonclin Drug Safety, Nutley, NJ USA ; Novartis Inst BioMed Res, E Hanover, NJ USA ; SOLVO Biotechnol, Budapest, Hungary ; Absorpt Syst LP, Exton, PA USA ; Simcyp, Sheffield, S Yorkshire, England ; Novartis Inst BioMed Res, Cambridge, MA USA ; Boehringer Ingelheim Pharmaceut Inc, Drug Metab & Pharmacokinet, Ridgefield, CT USA ; Genentech Inc, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA ; CellzDirect Life Technol Ltd, Austin, TX USA ; Biogen Idec Inc, Drug Metab & Pharmacokinet, Cambridge, MA USA ; Eisai Inc, Andover, MA USA ; R&D DSAR Drug Disposit FF, Sanofi Aventis, Frankfurt, Germany ; TNO, NL-3700 AJ Zeist, Netherlands ; Millennium Pharmaceut Inc, Cambridge, MA USA ; Merck Serono, Inst Drug Metab & Pharmacokinet, Grafing, Germany ; US FDA, Off Clin Pharmacol, Off Translat Sci, Ctr Drug Evaluat & Res, Silver Spring, MD USA ; Drug Metab & Pharmacokinet, King Of Prussia, PA USA ; Drexel Univ, Dept Biol, Philadelphia, PA 19104 USA; Bentz, J; Drexel Univ, Dept Biol, Philadelphia, PA 19104 USA
Date Deposited: 13 Oct 2015 13:12
Last Modified: 13 Oct 2015 13:12
URI: https://oak.novartis.com/id/eprint/22050

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.